arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

Twist Bioscience Corp

TWST
$115.73 ▲ +4.79 (+4.32%) at close
Healthcare ·Biological Products, (No Diagnostic Substances) ·USBiological Products, (No Diagnostic Substances)
10 Visible periods
31 Metrics
Peer-ranked Benchmarks
Price Chart
27
Health
Poor
Bearish
auto_awesome

Analytical Summary

Twist Bioscience Corp faces fundamental challenges with weakness in Profit Margin (%) and Operating Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $6.9B
Dividend Yield
Revenue Growth 20.3%
Op. Margin -36.2%
ROIC -29.1%
FCF / Share $-1.26
Trailing P/E
Price / Book 14.8x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Aug 7, 2026.

10-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$376.57M
↑ +20.3%
Net Income Profit after all expenses
$-77.67M
↑ +62.8%
Operating Margin Operating profit as % of sales
-36.2%
↑ +48.7% 7th
FCF / Share Free cash flow per share
$-1.26
↓ -6.1%
Long-Term Debt Long-term obligations
$1.40M
↓ -81.3%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile

Health Breakdown

Profitability
9
Returns
29
Cash Quality
64

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 10 years · 36 quarters